N-methoxy-N-methyl-1-azabicyclo[2.2.1]heptane-4-carboxamide | 126344-04-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-methoxy-N-methyl-1-azabicyclo[2.2.1]heptane-4-carboxamide
• 英文别名: 1-Azabicyclo[2.2.1]hept-4-yl-N-methoxy-N-methyl carboxamide
• CAS: 126344-04-5
• 化学式: C₉H₁₆N₂O₂
• 分子量: 184.238
• InChiKey: KGCBGVXKSIJIEB-UHFFFAOYSA-N

物化性质

• 沸点：
  236.3±42.0 °C(predicted)
• 密度：
  1.17±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-methoxy-N-methyl-1-azabicyclo[2.2.1]heptane-4-carboxamide 在 盐酸 、 lithium aluminium tetrahydride 、 sodium cyanoborohydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 为溶剂， 反应 2.17h， 生成
  参考文献：
  名称：

  JP6377570

  摘要：

  公开号：
• 作为产物：
  描述：

  7-苄基-2-噁-7-氮杂螺[4.4]-1-壬酮 在 palladium on activated charcoal 吡啶 、 盐酸 、 氯化亚砜 、 氢溴酸 、 氢气 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 N-methoxy-N-methyl-1-azabicyclo[2.2.1]heptane-4-carboxamide
  参考文献：
  名称：

  Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

  摘要：

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.

  DOI：

  10.1021/jm00091a007

文献信息

• Compounds
  申请人：Beecham Group p.l.c.

  公开号：US05166357A1

  公开（公告）日：1992-11-24

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which one of X and Y represents hydrogen and the other represents Z, where Z is a group ##STR2## in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one heteroatom selected from oxygen, nitrogen and sulphur or two heteroatoms selected from sulphur and nitrogen, any amino nitrogen being optionally substituted by a C.sub.1-2 alkyl, and at least one ring carbon atom being substituted by a group R.sub.1 ; or a group ##STR3## in which A.sub.1, A.sub.2 and A.sub.3 complete a 5-membered aromatic ring and A.sub.1 is oxygen or sulphur, A.sub.2 is CR.sub.2 and A.sub.3 is nitrogen or CH, or A.sub.2 is oxygen or sulphur, A.sub.1 is CH and A.sub.3 is CR.sub.2 ; and R.sub.1 and R.sub.2 are selected from, halogen, CN, OR.sub.4, SR.sub.4, N(R.sub.4).sub.2, NHCOR.sub.4, NHCOOCH.sub.3, NHCOOC.sub.2 H.sub.5, NHOR.sub.4 NHNH.sub.2, NO.sub.2, COR.sub.4, COR.sub.5, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl or C.sub.1-2 alkyl substituted with OR.sub.4, N(R.sub.4).sub.2, SR.sub.4, CO.sub.2 R.sub.4, CON(R.sub.4).sub.2 or one, two or three halogen atoms, in which each R.sub.4 is independently hydrogen or C.sub.1-2 alkyl and R.sub.5 is OR.sub.4, NH.sub.2 or NHR.sub.4 ; r represents an integer of 2 or 3, s represents an integer of 1 or 2 and t represents 0 or 1, with the proviso that when Y is hydrogen s is 1.

  公式（I）的化合物或其药学上可接受的盐：##STR1## 其中X和Y中的一个代表氢，另一个代表Z，其中Z是一个基团##STR2## 其中Q代表完成5-成员芳香环的3-成员二价残基，并包括从氧、氮和硫中选择的一个杂原子或从硫和氮中选择的两个杂原子，任何氨基氮可以选择性地被C.sub.1-2烷基取代，至少一个环碳原子被R.sub.1基团取代；或者一个基团##STR3## 其中A.sub.1，A.sub.2和A.sub.3完成5-成员芳香环，A.sub.1是氧或硫，A.sub.2是CR.sub.2，A.sub.3是氮或CH，或者A.sub.2是氧或硫，A.sub.1是CH，A.sub.3是CR.sub.2；R.sub.1和R.sub.2从卤素，CN，OR.sub.4，SR.sub.4，N（R.sub.4）.sub.2，NHCOR.sub.4，NHCOOCH.sub.3，NHCOOC.sub.2 H.sub.5，NHOR.sub.4 NHNH.sub.2，NO.sub.2，COR.sub.4，COR.sub.5，C.sub.2-4烯基，C.sub.2-4炔基或C.sub.1-2烷基中选择取代OR.sub.4，N（R.sub.4）.sub.2，SR.sub.4，CO.sub.2 R.sub.4，CON（R.sub.4）.sub.2或一个、两个或三个卤素原子，其中每个R.sub.4独立地代表氢或C.sub.1-2烷基，R.sub.5代表OR.sub.4，NH.sub.2或NHR.sub.4；r表示2或3，s表示1或2，t表示0或1，但当Y是氢时，s为1。
• Azabicyclic compounds for treating dementia
  申请人：Beecham Group p.l.c.

  公开号：US05217975A1

  公开（公告）日：1993-06-08

  A compound of formula (I) useful for treating dementia or a pharmaceutically acceptable salt thereof: ##STR1## in which one of X and Y represents hydrogen and the other represents Z, where Z is a group in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a C.sub.1-2 alkyl, cyclopropyl or propargyl group, r represents the integer of 2 or 3, s represents an integer of 1 or 2 and t represents 0, with the proviso that when Y is hydrogen s is 1.

  一种化合物的分子式（I），或其药学上可接受的盐，可用于治疗痴呆症：##STR1## 其中X和Y中的一个表示氢，另一个表示Z，其中Z是一个基团，其中Q表示完成5-成员芳香环的3-成员二价残基，并包括两个或三个氮原子，任何氨基氮均被C.sub.1-2烷基，环丙基或丙炔基取代，r表示2或3的整数，s表示1或2的整数，t表示0，但当Y为氢时，s为1。
• Azabicyclo oxime derivatives
  申请人：Beecham Group p.l.c.

  公开号：US05110828A1

  公开（公告）日：1992-05-05

  Novel compounds of formula (I), a process for their preparation, and their use as pharmaceutical agents are described: ##STR1## wherein R.sub.1 represents ##STR2## in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1; R.sub.2 is a group OR.sub.4, where R.sub.4 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, a group OCOR.sub.5 where R.sub.5 is hydrogen or R.sub.4, or a group NHR.sub.6 or NR.sub.7 R.sub.8 where R.sub.6, R.sub.7 and R.sub.8 are independently C.sub.1-2 alkyl; and R.sub.3 is hydrogen or C.sub.1-4 alkyl, subject to the proviso that when R.sub.2 is a group OCOR.sub.5 or a group NHR.sub.6, R.sub.3 is C.sub.1-4 alkyl.

  本发明涉及一种式（I）的新化合物，以及它们的制备方法和作为药物制剂的用途： 其中，R1表示如下：其中p和q各自独立地表示2至4的整数，r表示2至4的整数，s表示1或2，t表示0或1；R2是OR4基团，其中R4是C1-4烷基，C2-4烯基，C2-4炔基，OCOR5基团（其中R5是氢或R4），或NHR6或NR7R8基团（其中R6、R7和R8各自独立地是C1-2烷基）；R3是氢或C1-4烷基，但当R2是OCOR5基团或NHR6基团时，R3是C1-4烷基。
• 2-SUBSTITUTED CEPHEM COMPOUNDS
  申请人：GLAXO GROUP LIMITED

  公开号：US20150299223A1

  公开（公告）日：2015-10-22

  The present invention relates to 2-substituted cephem compounds of Formula (I) having a quaternary ammonium group on the 3-side chain, preferably together with a cathechol group, or pharmaceutically acceptable salts thereof, which exhibit potent antimicrobial spectrum against a variety of bacteria including Gram negative bacteria and/or Gram positive bacteria, corresponding pharmaceutical compositions, methods of making, treatment methods for bacterial infections or uses thereof.

  本发明涉及具有第3侧链上季铵基团的2-取代头孢菌素化合物（I）, 与儿茶酚基团一起更佳，或其药学上可接受的盐，对包括革兰氏阴性菌和/或革兰氏阳性菌在内的多种细菌具有强效的抗微生物谱，相应的制药组合物，制备方法，治疗细菌感染的方法或其用途。
• Novel compounds
  申请人：BEECHAM GROUP PLC

  公开号：EP0338723A1

  公开（公告）日：1989-10-25

  Novel compounds of formula (I), a process for their preparation, and their use as pharmaceutical agents are described: wherein R₁ represents in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1; R₂ is a group OR₄, where R₄ is C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, a group OCOR₅ where R₅ is hydrogen or R₄, or a group NHR₆ or NR₇R₈ where R₆, R₇ and R₈ are independently C₁₋₂ alkyl; and R₃ is hydrogen or C₁₋₄ alkyl, subject to the proviso that when R₂ is a group OCOR₅ or a group NHR₆, R₃ is C₁₋₄ alkyl.

  本研究描述了式 (I) 的新型化合物、其制备方法及其作为药剂的用途： 其中 R₁ 代表 其中 p 和 q 各自独立地代表 2 至 4 的整数，r 代表 2 至 4 的整数，s 代表 1 或 2，t 代表 0 或 1； R₂ 是基团 OR₄，其中 R₄ 是 C₁₋₄ 烷基、C₂₋₄ 烯基、C₂₋₄ 烷炔基、基团 OCOR₅（其中 R₅ 是氢或 R₄）或基团 NHR₆ 或 NR₇（其中 R₆、R₇ 和 R₈ 独立地是 C₁₋₂ 烷基）；以及 R₃ 是氢或 C₁₋₄ 烷基，但当 R₂ 是基团 OCOR₅ 或基团 NHR₆ 时，R₃ 是 C₁₋₄ 烷基。